TECHNOLOGY FOCUS - ELECTRONICS - Preferred Components: The light in method (M) and (M3) comprises a wavelength of about 300 to about 500 nm (preferably 300-360 or 450-500) nm. The light in method (M) or (M3) comprises visible light or infrared light. The light in method (M1) is sunlight, photo-optic light, or laser light; or is visible light or infrared light.    TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preparation: No general preparation of the ruthenium compounds is given in the specification. Preferred Compounds: The ruthenium compound is selected from (Ru(bpy)2(RhodB-MAPN)Cl)Z, (Ru(bpy)2(Rhod6G-MAPN)Cl)Z, and (Ru(bpy)2(RhodB-MAMePy)Cl)Z.Z=anion.    TECHNOLOGY FOCUS - INSTRUMENTATION AND TESTING - Preferred Vessel: The vessel further contains a biological sample (preferably organ, tissue, cell, or hair sample).    TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Method: The method (M1) for making an organic molecule bioavailable to a subject, involves administering the compound (V) to the subject; and exposing the compound to light to release the organic molecule from the compound, where the organic molecule has a 5-membered monocyclic aromatic ring, where one of the ring's members is a nitrogen atom that forms a bond with Ru; a 6-membered monocyclic aromatic ring, where one of the ring's members is a nitrogen atom that forms a bond with Ru; an 8-10-membered bicyclic ring, where one of the bicyclic rings is aromatic and has a nitrogen atom member that forms a bond with Ru; -NH2 group whose nitrogen atom forms a bond with Ru; COOH group, one of whose oxygen atoms forms a bond with Ru; a -PR2 group whose phosphorus atom forms a bond with Ru; or an -SR group whose sulfur atom forms a bond with Ru. The exposing in method (M) or (M3) occurs at a temperature of 0-150 degrees C. In method (M1), the exposing occurs at the site of a tumor, cancer, or neoplasm; or at the site of a blood dyscrasia. The method (M2) of treating disorders and diseases in a subject, involves administering the compound (V) to the subject; and exposing the compound to light to release the organic molecule from the compound, where the organic molecule has: a 5-membered monocyclic aromatic ring, where one of the ring's members is a nitrogen atom that forms a bond with Ru; a 6-membered monocyclic aromatic ring, where one of the ring's members is a nitrogen atom that forms a bond with Ru; an 8-10-membered bicyclic ring, where one of the bicyclic rings is aromatic and has a nitrogen atom member that forms a bond with Ru; -NH2 group whose nitrogen atom forms a bond with Ru; a -COOH group, one of whose oxygen atoms forms a bond with Ru; a -PR2 group whose phosphorus atom forms a bond with Ru; or -SR group whose sulfur atom forms a bond with Ru. The method (M4) for enhancing the solubility of an organic molecule, involves complexing an organic molecule to a photolabile caging group to form the compound (V), where exposing the compound to light releases the organic molecule from the compound, and where the organic molecule has a 5-membered monocyclic aromatic ring, where one of the ring's members is a nitrogen atom that forms a bond with Ru; a 6-membered monocyclic aromatic ring, where one of the ring's members is a nitrogen atom that forms a bond with Ru; an 8-10-membered bicyclic ring, where one of the bicyclic rings is aromatic and has a nitrogen atom member that forms a bond with Ru; -NH2 group whose nitrogen atom forms a bond with Ru; a -COOH group, one of whose oxygen atoms forms a bond with Ru; -PR2 group whose phosphorus atom forms a bond with Ru; or -SR group whose sulfur atom forms a bond with Ru. Preferred Components: The tissue is neuronal tissue. The cell is a neuronal cell. The tissue or cell is a tumor, cancer, or neoplastic tissue or cell. The biological sample is a body fluid sample. The body fluid sample is blood, serum, plasma, lymph, saliva, sputum, tears, semen, or urine. Full Definitions:    L1=organic molecule having a 5-membered monocyclic aromatic ring, where one of the ring's members is a nitrogen atom that forms a bond with Ru; a 6-membered monocyclic aromatic ring, where one of the ring's members is a nitrogen atom that forms a bond with Ru; an 8-10-membered bicyclic ring, where one of the bicyclic rings is aromatic and has a nitrogen atom member that forms a bond with Ru; -NH2 group whose nitrogen atom forms a bond with Ru; -COOH group, one of whose oxygen atoms forms a bond with Ru; -PR2 group whose phosphorus atom forms a bond with Ru or -SR group whose sulfur atom forms bond with Ru;    R=H, 1-18C alkyl, or aryl;    L2=(R9)3P, (R9O)3P, CN or L1; or is a labeling molecule or its active derivative connected to Ru through the phosphorus atom of (R9)2P or (R9O)2P; or a labeling molecule or its active derivative connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile; or is P(phenyl)3 or a labeling molecule or its active derivative connected to Ru through phosphorus atom of P(phenyl)2, where each phenyl is substituted with 1-18C alkyl, -(1-18C alkyl)-OH, aryl, -(1-18C alkyl)-oxy, -(1-18C alkyl)-amino, -(1-18C alkyl)-thio, -CO2Y', -C(=O)Y', -C(=O)NY'2, -NH2, -NO2, -OH, or -SH;    m=1 or 2;    R9=1-18C alkyl, 3-8C cycloalkyl, or phenyl;    R1 to R4=H, 1-18C alkyl; -NH2, -(1-18C alkyl)-O-(1-18C alkyl), -OC(O)(1-18C alkyl), -(1-18C alkyl)-OH, aryl, -(1-18C alkyl)-oxy, -(1-18C alkyl)-amino, -(1-18C alkyl)-thio, -CO2Y', -C(=O)Y', -C(=O)NY'2, -NO2, or -SH;or    R1+R2 and/or R3+R4=a carbocyclic ring substituted by at least one oxo;    X=Cl-, F-, Br-, I-, PF6-, CF3SO3-, (1-18C alkyl)-CO2-, or (1-18C alkyl)-SO3-;    Y'=H, 1-18C alkyl, aryl, -(1-18C alkyl)-aryl, 3-8C cycloalkyl, heteroaryl, or heterocyclyl;    L'2=P(phenyl)3, where each phenyl is substituted with -1-18C alkyl, -(1-18C alkyl)-OH, aryl, -(1-18C alkyl)-oxy, -(1-18C alkyl)-amino, -(1-18C alkyl)-thio, -CO2Y', -C(O)Y', -C(O)NY'2, -NH2, -NO2, -OH, or -SH; or is a labeling molecule or its active derivative connected to Ru through the phosphorus atom of (R9)2P or (R9O)2P; or is a labeling molecule or its active derivative connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile;    L2a=(R9)3P, (R9O)3P or L1; or is not P(phenyl)3; or is CN; or is a labeling molecule or its active derivative connected to Ru through the phosphorus atom of (R9)2P or (R9O)2P; or is a labeling molecule or its active derivative connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile;    R5 (not shown in structure)=1-18C alkyl, 3-8C cycloalkyl or phenyl;    L1b=labeling molecule or its active derivative connected to Ru through the phosphorus atom of (R9)2P or (R9O)2P; or is labeling molecule or its active derivative connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile;    L2b=Cl-, phosphine, OH2, or pyridine or CN.    Provided that:    (1) when L2 is (R9)3P, (R9O)3P, or L1, m is 2;    (2) when L2 is -CN, m is 1;    (3) when L2 is a labeling molecule or its active derivative connected to Ru through the phosphorus atom of (R9)2P or (R9O)2P, m is 2;    (4) when L2 is a labeling molecule or its active derivative connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile, m is 2;    (5) when L2 is P(phenyl)3 or a labeling molecule or its active derivative connected to Ru through the phosphorus atom of P(phenyl)2, each phenyl is substituted with 1-18C alkyl, -(1-18C alkyl)-OH, aryl, -(1-18C alkyl)-oxy, -(1-18C alkyl)- amino, -(1-18C alkyl)-thio, -CO2Y', -C(=O)Y', -C(=O)NY'2, -NH2, -NO2, -OH, or -SH;    (6) in compound (V), when L2 is not P(phenyl)3, R1 to R4 are -H, -(1-18C alkyl)-OH, aryl, -(1-18C alkyl)-oxy, -(1-18C alkyl)-amino, -(1-18C alkyl)-thio, -CO2Y', -C(=O)Y', -C(=O)NY'2, -NO2, -OH, or -SH;    (7) in compound (V) and (VII), at least one of R1 to R4 is not H;    (8) L'2 is a labeling molecule or its active derivative connected to Ru through the phosphorus atom of (R9)2P or (R9O)2P when m is 2; or L'2 is a labeling molecule or its active derivative connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile when m is 2;    (9) when L2a is (R9)3P, (R9O)3P or L1; or is labeling molecule or its active derivative connected to Ru through the phosphorus atom of (R9)2P or (R9O)2P; or is a labeling molecule or its active derivative connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile, m is 2;    (10) when L2a is CN, m is 1;    (11) when L1b is a labeling molecule or its active derivative connected to Ru through the phosphorus atom of (R9)2P or (R9O)2P, m is 2;    (12) when L1b is a labeling molecule or its active derivative connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile, m is 2;    (13) when L2b is Cl-, phosphine, OH2, or pyridine, m is 2;    (14) when L2b is -CN, m is 1.    Preferred Definitions:    L1=4-aminopyridine, (RS)-(tetrazol-5-yl) glycine, (tetrazol-5-yl) AMPA, nicotine or caffeine, serotonin, epinephrine, norepinephrine, or dopamine, adenosine 5'-diphosphate (ADP), adenosine 5'-triphosphate (ATP), adenosine 5'-monophosphate (AMP), cyclic adenosine 5'-diphosphate ribose, or adenosine 3',5'-cyclic monophosphate, aminobutyric acid or L-glutamic acid, or methyl-D-aspartic acid;    L2=L1 (preferably Rhodamine B-methylaminopropionitrileamide (RhodB-MAPN), Rhodamine 6G-methylaminopropionitrileamide (Rhod6G-MAPN), RhodB-MAMePy, Rhod6G-MAMePy or its salt);    L'2=P(phenyl)3, where each phenyl is substituted at the 3 or 4 position with -(1-18C alkyl)-OH, -COOH, OH, -NH2 or -NO2; or is labeling molecule or its derivative (preferably Rhodamine B-methylaminopropionitrileamide (RhodB-MAPN), Rhodamine 6G-methylaminopropionitrileamide (Rhod6G-MAPN), RhodB-MAMePy, Rhod6G-MAMePy or its salt);    L2a=P(methyl)(phenyl)2; or is labeling molecule or its derivative (preferably Rhodamine B-methylaminopropionitrileamide (RhodB-MAPN), Rhodamine 6G-methylaminopropionitrileamide (Rhod6G-MAPN), RhodB-MAMePy, Rhod6G-MAMePy or its salt);    L1b=fluorescent molecule that contains a -CN group whose nitrogen atom forms a bond with Ru, where the fluorescent molecule contains rhodamine, fluorescein or iodeosin;    L2b=labeling molecule or its derivative (preferably Rhodamine B-methylaminopropionitrileamide (RhodB-MAPN), Rhodamine 6G-methylaminopropionitrileamide (Rhod6G-MAPN), RhodB-MAMePy, Rhod6G-MAMePy or its salt).    WIDER DISCLOSURE - Also disclosed are new ruthenium compounds selected from 4 compounds as given in the specification e.g. compound of formula (I).    M=Ru;    R'1-R'8=H, 1-18C alkyl, NH2, COOH, 1-18C alkyl-O-1-18C alkyl or -OC(O)-1-18C alkyl.    ACTIVITY - Neuroprotective; Muscular-Gen.; Anticonvulsant; Cytostatic; CNS-Gen.; Antimigraine; Analgesic; Cerebroprotective; Vasotropic; Tranquilizer; Antidepressant; Antiaddictive; Neuroleptic; Antipruritic; Antiparkinsonian; Nootropic; Ophthalmological; Antiemetic; Cardiovascular-Gen.; Immunosuppressive; Hepatotropic; Antiinflammatory; Gastrointestinal-Gen.; Dermatological; Nephrotropic; Antirheumatic; Antiarthritic; Antialcoholic; Antibacterial; Anabolic; Eating-Disorders-Gen.; Virucide; Vulnerary; Antiulcer; Antidiabetic; Metabolic; Anti-HIV. Test details described no results given.    MECHANISM OF ACTION - None given.    ADMINISTRATION - In the method for making an organic molecule bioavailable to a subject, the compound is administered intravenously, topically, intradermally, intramuscularly, transdermally in the form of patch, subcutaneously, intranasally, parenterally, intrathecally, vaginally, rectally, colorectally, orally, intracranially, retro-orbitally, intrasternally, or by injection (claimed). The compounds are administered at a dosage of 0.01-1 mg/kg or at a dosage of 1 mu g to 50 mu g/kg intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, intranasally, epidurally, topically, transdermally, intrathecally, vaginally, rectally, colorectally, orally, intracranially, retro-orbitally, systemically, locally, intraventricularly, by intrathecal injection, by pulmonary route, by infusion, by implantation or intrasternally or parenterally at a dosage of 1 mu g/kg to 10 mg/kg.    SPECIFIC COMPOUNDS - 3 Compounds i.e. (Ru(bpy)2(RhodB-MAPN)Cl)Cl, (Ru(bpy)2(Rhod6G-MAPN)Cl)Cl, and (Ru(bpy)2(RhodB-MAMePy)Cl)Cl of formula (I') (where MAPN is methylaminopropionitrile amide) are specifically claimed as the photolabile ruthenium compounds.    EXAMPLE - Preparation of (Ru(bpy)2(L)Cl)PF6 (where L was Rhodamine B-methylaminopropionitrileamide) was carried out as follows: Twenty mg of Ru(bpy)2Cl2 were suspended in 2 ml of a 2:1 EtOH/water mixture and the suspension was heated to 80 degrees C until total dissolution. The formation of the (Ru(bpy)2(H2O)Cl)+ complex was determined by its absorption band at 490 nm (in water). After formation of the chloro-aquo complex, two equivalents of the RhodB-MAPN chloride salt were added, and the reaction was followed by TLC using silica plates and a mixture of 1:1:1 water/EtOH/n-BuOH as eluent. The solution was heated at 80 degrees C during about 2 hours, until no further TLC changes were observed. The solution was filtered and the solvent was removed under a vacuum. The obtained oil was re-dissolved in 4 ml of a 3:1 acetone:methanol mixture and was precipitated by addition of excess THF. The THF fraction containing unreacted ligand was discarded, and the precipitate was washed several times with THF, redisolved in water and precipitated with saturated KPF6 to form the compound (yield 26%).